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Introduction: Alpha-1 antitrypsin deficiency (AATD) remains an underdiagnosed condition 
despite initiatives developed to increase awareness. The objective was to describe the current 
situation of the diagnosis of AATD in primary care (PC) in Catalonia, Spain.
Methods: We performed a population-based study with data from the Information System for 
Development in Research in Primary Care, a population database that contains information 
of 5.8 million inhabitants (80% of the population of Catalonia). We collected the number of 
alpha-1 antitrypsin (AAT) determinations performed in the PC in two periods (2007–2008 and 
2010–2011) and described the characteristics of the individuals tested.
Results: A total of 12,409 AAT determinations were performed (5,559 in 2007–2008 and 6,850 
in 2010–2011), with 10.7% of them in children. As a possible indication for AAT determina-
tion, 28.9% adults and 29.4% children had a previous diagnosis of a disease related to AATD; 
transaminase levels were above normal in 17.7% of children and 47.1% of adults. In total, 
663 (5.3%) individuals had intermediate AATD (50–100 mg/dL), 24 (0.2%) individuals had a 
severe deficiency (,50 mg/dL), with a prevalence of 0.19 cases of severe deficiency per 100 
determinations. Nine (41%) of the adults with severe deficiency had a previous diagnosis of 
COPD/emphysema, and four (16.7%) were diagnosed with COPD within 6 months.
Conclusion: The number of AAT determinations in the PC is low in relation to the prevalence 
of COPD but increased slightly along the study period. The indication to perform the test is not 
always clear, and patients detected with deficiency are not always referred to a specialist.
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Introduction
Alpha-1 antitrypsin deficiency (AATD) is a congenital autosomical codominant 
condition characterized by low plasma levels of alpha-1 antitrypsin (AAT) in the blood 
and tissues. More than 120 genetic variants of the AAT gene have been identified 
and classified into three major categories: normal, with genotype M, characterized by 
AAT within normal ranges; deficient, characterized by reduced but detectable AAT 
plasma levels with genotypes Z, S, and M-like; and null, currently designated as Q0, 
with no detectable plasma levels.1 AATD is one of the most common congenital 
disorders with an estimated prevalence between one in 2,857 and one in 5,097 in 
USA1 and between one in 2,175 and one in 5,164 in Spain.2 AATD predisposes the 
development of certain diseases, especially COPD in adults and liver disease, which 
is more frequent in children. Other less frequent conditions associated with AATD 
are panniculitis, vasculitis, and fibromyalgia.1
The World Health Organization recommends the testing of all COPD patients,3 
and the European Respiratory Society and American Thoracic Society guidelines 
recommend the testing of all symptomatic adults with persistent airway obstruction, 
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such as COPD, emphysema, and asthma with incompletely 
reversible airflow obstruction, individuals with unexplained 
liver disease, and adults with necrotizing panniculitis or 
multisystemic vasculitis.1 Similarly, the Spanish Society of 
Pneumology and Thoracic Surgery (SEPAR) recommends 
that all COPD patients should be tested at least once in their 
lives.4 Despite these recommendations, AATD is significantly 
underdiagnosed, and most of the patients are detected long 
after the onset of pulmonary or liver disease. Another impli-
cation of this late diagnosis is the delay in the detection of 
affected relatives, which hinders the implementation of 
measures, such as abstaining from tobacco exposure.5,6
Underdiagnosis of AATD is a challenge, particularly, for 
primary care (PC) physicians who attend most of the COPD 
patients, and this is usually the first point of contact of patients 
with health care providers. Computerized databases of 
medical records are increasingly used in clinical research to 
enhance the knowledge about the management and progres-
sion of this disease based on real-life data.7 Database studies 
help to understand real clinical practice and to design public 
health strategies to improve the quality of care. The objec-
tive of this study was to describe the patterns of diagnosis 
of AATD in PC in Catalonia, Spain.
Methods
This was an epidemiological, population-based, observa-
tional study aimed to quantify and compare the number 
of AAT determinations performed in the PC in Catalonia 
during two 2-year periods (2007–2008 and 2010–2011) and 
to describe the characteristics of the individuals tested and 
the management of those with deficient values. Data for this 
study were obtained from the System for the Development of 
Research in Primary Care (SIDIAP) database, a computer-
ized database containing anonymized patient records for the 
5.8 million people registered in the 279 PC centers of the 
Catalan Health Institute (.80% of Catalonia’s population). 
All general practitioners in the Catalan Health Institute use 
the same specific software called eCAP to record the clinical 
information of their patients. Health professionals gather this 
information using codes of International Statistical Clas-
sification of Diseases and Related Health Problems, Tenth 
Revision, and structured forms designed for the collection of 
variables. SIDIAP combines information from the electronic 
medical records with data from other databases and registers, 
such as laboratory test results (from the laboratory databases), 
the pharmacy register, and the National Mortality Register.8,9 
For the purpose of the study, we checked the quality of the 
SIDIAP database. High-quality data were obtained from 
2007 onward; however, data from 2012 were not available at 
the time of the initiation of the study. Therefore, to compare 
two periods of the same length, we used data from 2007 to 
2008 and 2010 to 2011. The study was approved by IDIAP 
Jordi Gol Ethics Committee (Barcelona, Spain). This was a 
retrospective study with data from an anonymized database, 
so it was not necessary to request patient consent.
Population
All the individuals with an AAT determination during the study 
period were included. Based on the levels obtained in the deter-
mination, individuals were classified as follows: no deficiency: 
AAT .100 mg/dL; intermediate deficiency: AAT between 
50 mg/dL and 100 mg/dL; and severe deficiency: AAT 
,50 mg/dL.10 Since indications for AAT testing differ by 
age group, we classified individuals younger than 15 years as 
children and analyzed them separately. Demographic and clini-
cal characteristics were recorded for all the study populations. 
For individuals with intermediate and severe deficiencies, 
we collected data on referrals to a specialist, complementary 
tests (spirometry and computerized tomography scans), 
pharmacologic treatment, and number of respiratory infections 
during the 6 months following the determination.
statistical analysis
A descriptive analysis of each period (2007–2008 and 
2010–2011) and of the totality of the sample was performed 
separately for children and adults. For qualitative variables, 
absolute frequencies and corresponding percentages were 
calculated. Quantitative variables following a normal distri-
bution were described by mean and standard deviation, while 
those not following a normal distribution were described 
using the median and 25–75 percentiles. Differences between 
groups were performed using the chi-square test for categori-
cal variables, while continuous variables were tested using 
the Student’s t-test (or the Mann–Whitney U-test, if the 
variables were not normally distributed). All tests were two-
tailed, and significance was set at 5%. All statistical analyses 
were performed using a statistical software package (SPSS 
Version 20.0; IBM Corporation, Armonk, NY, USA).
Results
Frequency of aaT determinations
In total, 12,409 determinations of serum AAT were per-
formed during the 4 years of the study, of which 1,335 
(10.7%) were children. The number of determinations 
was higher in the second period (5,559 determinations in 
2007–2008 and 6,850 determinations in 2011–2011) due 
to the low number of individuals tested in 2007. Nonethe-
less, the rate of individuals tested per year did not increase 
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significantly after 2008 (Table 1). Figure 1 shows the number 
of determinations performed by age groups.
Characteristics of the individuals tested
The mean age of the individuals tested was 52.6 (SD 
16.3) years in adults and 4.6 (SD 4.1) years in children, with 
an equal distribution between sexes. Among adults, 37.1% 
were smokers or former smokers. The most frequent comor-
bidities in adults were dyslipidemia (27.6%), hypertension 
(27.4%), diabetes mellitus (11.7%), depression (10.1%), 
and ischemic heart disease (4%). Up to 41% of children and 
18.5% of adults were receiving treatment for a respiratory 
disease at the time of the determination. The majority of the 
determinations were performed in urban areas. Demographic 
characteristics are shown in Tables 2 and 3.
Indications for aaT determinations, aaT 
concentrations, and follow-up
As a possible indication for AAT determination, 3,195 
(28.9%) adults and 393 (29.4%) children had a previous diag-
nosis of a disease related to AATD. Up to 17.7% of children 
and 47.1% of adults had transaminase levels above normal 
(Tables 2 and 3). Nine percent of children were between the 
age 0 year and 1 year, suggesting neonatal jaundice as the 
most likely indication. During the previous year, 31.3% of 
individuals had had at least one respiratory infection and 
1.3% had had pneumonia.
The mean AAT plasma level was 147.2 (36.7) mg/dL 
in adults and 154.1 (37.2) mg/dL in children. In total, 663 
(5.3%) individuals (56 children) had an intermediate AAT 
deficiency, while 24 (0.2%) individuals (two children) had a 
severe deficiency, with a prevalence of 0.19 cases of severe 
deficiency per 100 determinations. Patients with severe 
deficiency were younger than individuals with normal AAT 
levels (42.5 years vs 52.9 years, P=0.003) and were more 
likely to have a previous diagnosis of COPD or emphysema 
(45.5% vs 10.8%, P,0.05) (Table 3).
During the 6-month follow-up, four of the patients with 
severe deficiency (18.1%) were newly diagnosed with COPD 
or emphysema, two (9.1%) following diagnostic spirometry 
and one (4.2%) after a computerized tomography scan. Only 
three patients (13.6%) were referred to a pneumologist and 
another patient was referred to internal medicine (Table 4).
Discussion
The results of this study show that the number of AAT deter-
minations performed in the PC in Catalonia, Spain, is low 
and has not increased after 2008. In addition, in most cases, 
we could not identify the reason for requesting the test, and 
after detection of a severe deficiency, some individuals were 
not tested further or referred to a specialist.
AATD is one of the most common congenital disor-
ders but remains significantly underdiagnosed despite the 
Table 1 number of aaT determinations performed by year
Period Children Adults Total n/10,000 inhabitants
2007 331 1,998 2,329 4.33
2008 382 2,848 3,230 6.85
2007–2008 713 4,846 5,559
2010 325 3,351 3,676 6.77
2011 297 3,676 3,174 5.82
2010–2011 622 6,228 6,850
Abbreviation: aaT, alpha-1 antitrypsin.
Figure 1 Distribution of percentage of aaT determinations performed by age group.
Abbreviation: aaT, alpha-1 antitrypsin.





recommendations of national and international guidelines.1,2 
Moreover, there is still a large delay between the onset of 
symptoms and diagnosis,11 with no significant improvement 
in this delay during the last decades.12 In Spain, it is estimated 
that 12,026 patients have a severe deficiency,13 with ~1,700 of 
these cases corresponding to Catalonia alone.14 Nonetheless, 
only 511 cases from all over the country are diagnosed and 
included in the Spanish registry for AATD.15
Possible explanations for the underdiagnosis of AATD 
have been addressed in previous studies. Knowledge of 
AATD is generally poor even for trainees who declared a 
special interest in respiratory medicine.16 Among nonpul-
monologists, awareness of AATD is low in comparison with 
other respiratory diseases,17 with the consequent low rate of 
testing for AATD.11,12,18 A survey carried out in Spain and Por-
tugal showed that the main reasons for not testing for AATD 
are the referral of patients to other specialists for testing or 
the erroneous perception of the high cost of the test.19
Despite the current recommendations of testing symptom-
atic adults with persistent airway obstruction and individuals 
with unexplained liver disease,1,2 the rate of AAT determina-
tions observed in our study along the years varied from 4.33 
determinations per 10,000 inhabitants in 2007 to 6.85 deter-
minations per 10,000 inhabitants in 2008, with intermediate 
values for 2010 and 2011. Data from a recent study performed 
with data from SIDIAP indicated that a mean of 6,932 new 
patients were diagnosed with COPD per year between 2007 
and 2012, a figure well above the 375 mean number of COPD 
patients tested yearly for AATD during the 4 years of our 
study.9 Although underdiagnosis of the deficiency has been 
reported in many countries, to our knowledge, this low rate 
of AAT determinations in the general population and in 
COPD patients has not been previously reported, thereby not 
allowing comparison of our findings with data from other 
countries or geographical areas.
Regarding the reasons for requesting AAT determination, 
we observed that only 13% of the adults tested had COPD, 
Table 2 Demographic characteristics and diseases related to 
aaTD of children tested for aaT during the study period
Variables Children (n=1,335)
Mean age (sD) 4.61 (4.1)
sex (males) 769 (57.6)
Urban setting 868 (65)
smokers 12 (0.9)






high transaminase levels 236 (17.7)
Note: Data are shown as n (%) unless specified otherwise.
Abbreviations: AAT, alpha-1 antitrypsin; AATD, alpha-1 antitrypsin deficiency.
Table 3 Comparison of the characteristics of adult patients tested for aaT during the study period according to aaT levels








age, mean (sD) 52.9 (16.3) 48.0 (14.4)** 42.5 (15.7)** 52.6 (16.3)
sex (males) 5,756 (55.1) 377 (62.1)** 14 (63.6) 6,147 (55.5)
smoker 2,219 (21.2) 113 (18.6) 7 (31.8) 2,339 (21.1)
Former smoker 1,668 (16) 101 (16.6) 3 (13.6) 1,772 (16)
aaT (mg/dl), mean (sD) 150.9 (34.2) 87.6 (10.8) 27.6 (11.6) 147.2 (36.7)
Previous diseases related to AATD
COPD 937 (9) 34 (5.6)* 6 (27.3)* 977 (8.8)
emphysema 193 (1.8) 14 (2.3) 4 (18.2)** 211 (1.9)
Chronic bronchitis 293 (2.8) 14 (2.3) 0 307 (2.8)
Bronchiectasis 284 (2.7) 11 (1.8) 0 295 (2.7)
asthma 794 (7.6) 45 (7.4) 3 (13.6) 842 (7.6)
hepatitis 768 (7.4) 32 (5.3) 1 (4.5) 801 (7.2)
Cirrhosis 127 (1.2) 3 (0.5) 0 130 (1.2)
hepatocarcinoma 4 (0) 0 0 4 (0)
high transaminase levels 5,430 (52) 313 (51.6) 8 (36.4) 5,751 (51.9)
Previous respiratory infections 3,486 (33.8) 162 (26.6)* 9 (40.9) 3,657 (33.02)
Previous pneumonia 136 (1.6) 5 (0.8) 1 (4.5) 142 (1.3)
hypertension 2,908 (27.8) 126 (20.8)** 2 (9.1)* 3,036 (27.4)
Dyslipidemia 2,901 (27.8) 158 (26) 2 (9.1)* 3,061 (27.6)
DM 1,247 (11.9) 44 (7.2)** 1 (4.5) 1,292 (11.7)
Depression 1,070 (10.2) 51 (8.4) 2 (9.1) 1,123 (10.1)
Ischemic heart disease 428 (4.1) 13 (2.1)** 0 441 (4)
Notes: *P,0.05 and **P,0.01 compared to individuals with normal AAT levels. Data are expressed as n (%) unless specified otherwise.
Abbreviations: AAT, alpha-1 antitrypsin; AATD, alpha-1 antitrypsin deficiency; DM, diabetes mellitus.
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chronic bronchitis, or emphysema and half had high 
transaminase levels, which could justify the request for 
AAT determination. These results concur with the observa-
tion that .70% of PC physicians in Spain were aware of 
liver complications of AATD, but very few decided to test 
all COPD patients.19 Similarly, only 0.5% of children had a 
codified liver disease at the time of AAT determination, and 
interestingly, the number of children tested for transaminitis 
and asthma was similar, although AATD is not a recognized 
cause of respiratory diseases in childhood.20
In an attempt to improve the rate of diagnosis of AATD 
in COPD, several screening initiatives or case findings have 
been developed,21–25 some being carried out in the PC.22,23 
In the IDDEA project of case finding of AATD in COPD 
patients, volunteer PC physicians were provided with filter 
paper to collect dried blood spots, together with informa-
tion about AATD and a Web tool. The ratio of recruitment 
only reached 6.6 patients per participant over the 9-month 
collection period, being somewhat low considering that the 
estimated prevalence of COPD in Spain is 10.2% of adults 
older than 40 years.26 However, among the individuals tested, 
4% were carriers of the severe deficient allele Z, and 0.34% 
were diagnosed with severe homozygous PiZZ deficiency.23 
Jain et al24 implemented an electronic alert to encourage 
guideline-based testing for AATD. This alert was displayed 
for patients with obstructive spirometry results, and this tool 
was associated with an increase in the frequency of testing.
Other strategies, such as programs to educate respiratory 
physicians27 and the combination of an awareness program 
with the offer of free diagnostic testing,28 resulted in high 
rates of detection of individuals with severe AATD. Popula-
tion screening programs in areas of high prevalence or proto-
cols to measure and phenotype AAT in selected patients were 
found to be effective at detecting AATD patients.29–31
Table 4 six-month follow-up of adults tested for aaTD according to aaT levels
Diagnosis after  
AAT determination






COPD 106 (1) 5 (0.8) 2 (9.1)*
emphysema 36 (0.3) 1 (0.2) 2 (9.1)**
Chronic bronchitis 18 (0.2) 2 (0.3) 0
respiratory infections 3,090 (29.5) 148 (24.4)** 10 (45.5)*
Pneumonia 58 (0.6) 3 (0.5) 0
spirometry 407 (2.9) 24 (4) 2 (9.1)
referrals
Pneumology 229 (2.2) 22 (3.6)* 3 (13.6)*
gastroenterology 489 (4.7) 42 (6.9)* 0
Internal medicine 73 (0.7) 2 (0.3) 1 (4.5)
Notes: *P,0.05 and **P,0.01 compared to individuals with normal levels of aaT. Data are expressed as n (%).
Abbreviations: AAT, alpha-1 antitrypsin; AATD, alpha-1 antitrypsin deficiency.
Our study has some limitations. First, the reason to 
request a complementary test is not recorded in the SIDIAP 
database, and we cannot be completely certain of the indica-
tion leading to the AAT determination. We can only assume 
the reason based on the codified diagnosis or the results of 
liver function tests. Second, databases are also subject to 
possible diagnostic and miscoding biases.32 However, consid-
ering that our main objective was to quantify the number of 
AAT determinations performed, we believe that this possible 
bias had little impact, if any, on the main objective of the 
study. On the other hand, the SIDIAP database includes data 
from .80% of the population of our area, thereby ensuring 
the representativeness of the results for the whole population 
of Catalonia.
Conclusion
Our study shows that the rate of testing for AAT in PC is still 
low, and the reasons for requesting the determination often 
remain unclear. These results should help to design interven-
tions to increase the awareness and the diagnosis of AAT in 
selected individuals or populations according to the current 
guidelines for the diagnosis and management of AATD.
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